Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Web3 Investment Fund C1 Fund Debuts on the NYSE, China Renaissance Serves as the Sole Underwriter in Asia

Web3 Investment Fund C1 Fund Debuts on the NYSE, China Renaissance Serves as the Sole Underwriter in Asia

ChaincatcherChaincatcher2025/08/08 07:10
Show original

According to ChainCatcher, C1 Fund (CFND), a private equity investment firm focused on Web3 and digital asset services, has successfully gone public on the New York Stock Exchange. The IPO issued 6 million shares at a price of $10 per share, raising a total of approximately $60 million. China Renaissance served as the sole underwriter for Asia in this IPO.

C1 Fund plans to invest at least 80% of its total assets in equity of companies within the Web3 and digital asset services technology sector, targeting investments in 30 leading enterprises. The fund’s core team includes former exchange Chief Legal Officer Michael Lempres (Chairman), Dr. Najam Kidwai (Chief Executive Officer), Klickl CEO Michael Zhao (Vice Chairman), and former Goldman Sachs executive Elliot Han (Chief Investment Officer), among other seasoned professionals.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage